Incyte lands $50M milestone for RA drug; H5N1 vaccine wins backing of FDA advisers; The Havana biotech hub?;

Conversation on Twitter :

 @FierceBiotech: From FierceBiotechIT.com: PPD secures adaptive trials software as clinical studies evolve. More | Follow @FierceBiotech

 @JohnCFierce: After FDA rejection, Bristol-AstraZeneca team wins E.C. OK for diabetes drug dapagliflozin--new hope for SGLT2 drugs. News | Follow @JohnCFierce

 @RyanMFierce: 10 trends in diagnostics from FierceBiotech. #1: Companion Dx. Special Report | Follow @RyanMFierce

> Incyte ($INCY) landed a $50 million milestone from Eli Lilly ($LLY) following the launch of the Phase III program for the rheumatoid arthritis drug baricitinib. Release

> GlaxoSmithKline ($GSK) has received the unanimous backing of an FDA advisory committee for its experimental H5N1 vaccine. "GSK has been collaborating with the U.S. Department of Health and Human Services since 2006 to develop this H5N1 vaccine and we are pleased with the positive vote recommending its approval" commented GSK's Bruce Innis. "We now look forward to a final decision by the FDA later this year and to also continuing our collaboration with the U.S. Government on public health issues." Release

> The Financial Times covers Cuba's long-running effort to create a biotech hub in the Caribbean country. Story

> Merck KGaA is already seeing the payoff from cost cuts. The German drugmaker beat expectations on third-quarter earnings, thanks in part to lower costs. Higher drug prices helped, too. In fact, the company raised its outlook for the year because of increased demand for its drugs, Bloomberg reports. Story

Pharma News

@FiercePharma: Slovenia's Krka expects 2012 profits to fall short, but sees 6% sales hike in 2013; plans hiring, new plants. Article | Follow @FiercePharma

> Merck KGaA sees job cuts, price hikes pay off in Q3. Story

> Buyout talk swirls around Amarin, with AZ and Teva rumored buyers. Report

> Email or snail mail from pharma? Docs like both, study finds. Article

Medical Device News

 @FierceMedDev: As advocates fight to repeal the device tax, we take a detailed look at how the 2.3% charge would work. Special Report | Follow @FierceMedDev

 @MarkHFierce: Hansen Medical, maker of the Magellan Surgical Robot, raised $10M in a new offering. More | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics broke ground on the first phase of its $300M Indianapolis expansion. News | Follow @DamianFierce

> Study: CardioDx's test helps guide cardiology decisions. Story

> Report: U.S. government incentives will spur robust infusion pump sales. Item

Pharma Manufacturing News

> Call for counterfeit drug treaty gets group banned from WHO event. Article

> Regeneron invests $80 million in plant, office project. News

> Promega expands with new China plant. Item

> Genzyme manufacturing upgrades again paying off. Story

Vaccines News

 @AlisonBFierce: Inovio Pharmaceuticals, a developer of synthetic vaccines, expanded its existing license agreement with UPenn. More | Follow @AlisonBFierce

> FDA: Dynavax's Heplisav effective against hepatitis B. Report

> Meningitis vaccine ruled safe for warm storage. Article

> Takeda sets sights on the vaccine market. More

> GSK's rotavirus vaccine selected for British program. News

> GSK reports lackluster PhIII malaria vaccine data. Story

And Finally… Investigators say they've discovered a gene variant that significantly raises the risk of Alzheimer's. Story

 

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.